Werewolf Therapeutics, Inc.HOWLNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Gross Profit Growth | -100.00% | -100.00% | -253.24% | -158.93% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +22.58% | +21.62% | +7.74% | +3.36% | +4.04% |
| Weighted Average Shares Diluted Growth | +22.58% | +21.62% | +7.74% | +3.36% | +4.80% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -20.61% | -27.40% | -39.62% | -39.78% | -43.14% |
| Book Value per Share Growth | -35.15% | -45.82% | -54.76% | -61.43% | -68.15% |
| Debt Growth | -29.53% | -28.57% | -27.81% | +1.28% | +1.42% |
| R&D Expense Growth | +15.59% | +62.99% | +1.64% | -13.93% | -7.14% |
| SG&A Expenses Growth | +6.64% | +6.13% | +7.48% | +0.48% | -10.97% |